Regeneron Pharmaceuticals, Inc. $REGN Position Cut by Groupe la Francaise

Groupe la Francaise lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 45.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,356 shares of the biopharmaceutical company’s stock after selling 3,671 shares during the period. Groupe la Francaise’s holdings in Regeneron Pharmaceuticals were worth $2,277,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. PGGM Investments lifted its holdings in Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Founders Capital Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares in the last quarter. Sepio Capital LP lifted its stake in Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the last quarter. Generate Investment Management Ltd bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $6,300,000. Finally, Bellecapital International Ltd. grew its position in Regeneron Pharmaceuticals by 32.7% in the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after buying an additional 6,283 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on REGN. Scotiabank raised their price objective on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a research note on Monday, November 24th. Bank of America lifted their price target on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein upped their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 23rd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $758.41.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $723.67 on Thursday. The business’s 50-day moving average is $644.26 and its 200-day moving average is $586.74. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The company has a market capitalization of $76.06 billion, a price-to-earnings ratio of 17.33, a P/E/G ratio of 2.15 and a beta of 0.37. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same period last year, the company posted $12.46 earnings per share. The firm’s quarterly revenue was up .9% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.